Acadia Pharmaceuticals Inc (NASDAQ: ACAD) open the trading on Wednesday, with a bit cautious approach as it glided -1.58% to $14.29, before settling in for the price of $14.52 at the close. Taking a more long-term approach, ACAD posted a 52-week range of $14.31-$32.59.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 27.73%. Meanwhile, its Annual Earning per share during the time was 28.03%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 247.16%. This publicly-traded company’s shares outstanding now amounts to $164.65 million, simultaneously with a float of $164.61 million. The organization now has a market capitalization sitting at $2.37 billion.
Acadia Pharmaceuticals Inc (ACAD) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. Acadia Pharmaceuticals Inc’s current insider ownership accounts for 0.76%, in contrast to 97.84% institutional ownership. According to the most recent insider trade that took place on Aug 19 ’24, this organization’s EVP, CHIEF FINANCIAL OFFICER sold 9,733 shares at the rate of 15.28, making the entire transaction reach 148,720 in total value, affecting insider ownership by 43,735. Preceding that transaction, on Aug 19 ’24, Company’s EVP, COO, HEAD OF COMMERCIAL sold 9,534 for 15.28, making the whole transaction’s value amount to 145,680. This particular insider is now the holder of 52,177 in total.
Acadia Pharmaceuticals Inc (ACAD) Earnings and Revenue Records
Acadia Pharmaceuticals Inc’s EPS increase for this current 12-month fiscal period is 247.16% and is forecasted to reach 0.82 in the upcoming year.
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) Trading Performance Indicators
Let’s observe the current performance indicators for Acadia Pharmaceuticals Inc (ACAD). It’s Quick Ratio in the last reported quarter now stands at 1.95. The Stock has managed to achieve an average true range (ATR) of 0.46. Alongside those numbers, its PE Ratio stands at $80.06, and its Beta score is 0.37. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 2.66. Similarly, its price to free cash flow for trailing twelve months is now 29.45.
In the same vein, ACAD’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 0.18, a figure that is expected to reach 0.14 in the next quarter, and analysts are predicting that it will be 0.82 at the market close of one year from today.
